Publication
The influence of insulin-like Growth Factor-1-Receptor expression and endocrine treatment on clinical outcome of postmenopausal hormone receptor positive breast cancer patients: A Dutch TEAM substudy analysis.
Authors not recorded
Mol Oncol2016PMID 26706833PMC5423148stubpubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
No abstract stored. Read on PubMed
Linked entities
Linked entities (5)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 5
- cancerMalignant Breast Neoplasmcivic_curation1.00
- drugExemestanecivic_curation1.00
- drugMetformincivic_curation1.00
- geneIGF1Rcivic_curation1.00
- variantIGF1R Overexpressioncivic_curation1.00
Curated evidence
Evidence citing this paper (1)
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 26706833
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| IGF1R Overexpression1 | ||||||||
| Exemestane + MetforminCombination | Malignant Breast Neoplasm | Predictive | B | Supports Sensitivity Response | 4 | accepted | EID10138A randomized phase III trial of hormone sensitive (ER or PR positive) early stage breast cancer (Dutch TEAM cohort, n=2,446) examined the addition of metformin to exemestane for 155 patients. IGF1R IH… (full text at CIViC) PMID 26706833 · Engels et al., 2016 · Open in CIViC | civic |